Companies › Ribocure Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 2; Cardiovascular, Infectious disease; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RBD5044 | – | Phase 2 | Dyslipidemias | May 2027 |
| RBD1016 Unclear - no mechanism stated | – | Phase 2 | Chronic Hepatitis D | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06797401 | RBD5044 | Phase 2 | Dyslipidemias | Cardiovascular | May 2027 |
| NCT06649266 | RBD1016 | Phase 2 | Chronic Hepatitis D | Infectious disease | Aug 2027 |
No annotated target.
–
TaiMed Biologics Suzhou HepaThera Biotech Hyundai Bioscience Cardurion Pharmaceuticals Research Institute of Geroprotective Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.